Isoprostenes as indicators of oxidative stress in schizophrenia

References

• Akyol O, Herken H, Zu E, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuro-Psychopharmacol Biol Psychiatr 2002; 26: 995–1005
   PubMed Web of Science ®Google Scholar
• Basu S. Isoprostanes: novel bioactive products of lipid peroxidation. Free Radic Res 2004; 38: 105–122
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Devillier P, Durand T, Stanke-Labesque F, Bessard G. Vascular biology of the isoprostanes. J Vasc Res 2001; 38: 93–103
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002; 23: 1–4
   PubMedGoogle Scholar
• Davi G, Falco A, Patrono C. Determinations of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 2004; 128: 149–163
   PubMed Web of Science ®Google Scholar
• Deminisch L, Gerbaldo H, Gebhart P, Georgi K, Bochnik HJ. Incorporation of 14C-arachidonic acid into platelet phospholipids of untreated patients with schizophrenic form or schizophrenic disorders. Psychiatr Res 1987; 22: 275–282
   PubMedGoogle Scholar
• Dietrich-Muszalska A, Rabe-Jablonska J, Zgirski A. Wpływ dzialania olanzapiny (Zolafren) na peroksydacje lipidów w ludzkich płytkach krwi i osoczu w układzie in vitro. Psychiatria i Psychologia Kliniczna 2004; 4: 13–19
   Google Scholar
• Dietrich-Muszalska A, Olas B, Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005; 16: 386–391
   PubMed Web of Science ®Google Scholar
• Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale 2006; 32: 244–252
   PubMed Web of Science ®Google Scholar
• Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatr 2000; 47: 8–21
   PubMed Web of Science ®Google Scholar
• Funk CD. Platelet eicosanoids. Hemostasis and thrombosis. Basic principles and clinical practice. Chapter 30, RW Colman, J Hirsh, VJ Marder, AW Clowes, JN George. Lippincott Williams & Wilkins, Philadelphia, PA 2001; 533–539
   Google Scholar
• Gao L, Yin H, Milne GL, Porter NA, Morrow JD. 2006. Formation of f-ring isoprostane-like compounds (F3-isoprostanes) in vivo from eicosapentaenoic acid. JBC on line M601035200, 1–19.
   Google Scholar
• Glen AIM, Glen EMT, Horrobin DF, et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 1994; 12: 53–61
   PubMed Web of Science ®Google Scholar
• Greco A, Minghetti L, Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res 2000; 25: 1357–1364
   PubMed Web of Science ®Google Scholar
• Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukotr Essent Fatty Acids 1996; 55: 3–7
   PubMed Web of Science ®Google Scholar
• Horrobin DF. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; 1: 936–937
   PubMed Web of Science ®Google Scholar
• Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatr 1991; 30: 795–805
   PubMed Web of Science ®Google Scholar
• Jeding I, Evans PJ, Akanmu D, et al. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol 1995; 49: 359–365
   PubMed Web of Science ®Google Scholar
• Khan NS, Das I. Oxidative stress and superoxide dismutase in schizophrenia. Biochem Soc Trans 1997; 25: 418S
   Google Scholar
• Kropp S, Kern V, Lange K, et al. Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsychiatry 2005; 17: 227–231
   PubMed Web of Science ®Google Scholar
• Lachance PA, Nakat Z, Jeong WS. Antioxidants: an integrative approach. Nutrition 2001; 17: 835–838
   PubMed Web of Science ®Google Scholar
• Mahadik SP, Mukherjee S, Correnti E, Scheffer R. Elevated levels of lipid peroxidation products in plasma of drug-naïve patients at the onset of psychosis. Schizophr Res 1995; 15: 66
   Web of Science ®Google Scholar
• Mahadik SP, Mukherjee S, Scheffer RS, Correnti EE, Mahadik JS. Elevated plasma lipid peroxidation at the onset of nonaffective psychosis. Biol Psychiatr 1998; 43: 674–570
   PubMed Web of Science ®Google Scholar
• Mehrabi MR, Serbecic N, Ekmekcioglu C, et al. The isoprostane 8-epi-PGF2α is a valuable indicator of oxidative injury in human heart valves. Cardiovasc Pathol 2001; 10: 241–245
   PubMedGoogle Scholar
• Milne GL, Morrow JD. Isoprostanes and related compounds: update 2006. Antioxidants Redox Signaling 2006; 8: 1379–1384
   PubMed Web of Science ®Google Scholar
• Morrow JD. The isoprostanes – unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Curr Pharm Design 2006; 12: 895–902
   PubMed Web of Science ®Google Scholar
• Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383–9387
   PubMed Web of Science ®Google Scholar
• Oguogho A, Ferlitsch A, Sinzinger H. LDL-apheresis decreases plasma levels and urinary extretion of 8-epi-PGF2α. Prostaglandins Leukotr Essent Fatty Acids 2000; 62: 209–216
   PubMedGoogle Scholar
• Peet M, Laugharne J, Rangarajan N, Reynolds GP. Tardive dyskinesia, lipid peorxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychophamacol 1993; 8: 151–153
   PubMed Web of Science ®Google Scholar
• Pratico D, Rokach J, Lawson J, FitzGerald GA. F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids 2004; 128: 165–171
   PubMed Web of Science ®Google Scholar
• Reddy RD, Yao JK. Membrane protective strategies in schizophrenia: conceptual and treatment issues. Phospholipid spectrum disorder in psychiatry, M Peet, I Glen, DF Horrobin. Marius Press, LancashireUK 1999; 75–88
   Google Scholar
• Reilly MO, Lawson JA, FitzGerald GA. Eicosanoids and isoeicosanoids: indices of cellular function and oxidant stress. J Nutr 1998; 128: 434–438S
   Google Scholar
• Robers LJ II, Morrow JD. Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation. Cell Mol Life Sci 2002; 59: 808–820
   Google Scholar
• Roberts LJ II, Reckelhoff JF. Measurement of F2-isoprostanes unveils profound oxidative tsress in adged rats. Biochem Biohys Res Comm 2001; 287: 254–256
   PubMed Web of Science ®Google Scholar
• Roberts LJ II, Montine TJ, Markesbery WR, et al. Formation of isoprostanes-like compounds (neuroprostanes) in vivo from oxidation of docosahexaenoic acid. J Biol Chem 1998; 273: 13605–13612
   PubMed Web of Science ®Google Scholar
• Rokach J, Khanapure SP, Hwang SW, Adiyaman M, Lawson JA, FitzGerald GA. The isoprostanes: a perspective. Prostaglandins 1997; 54: 823–851
   PubMedGoogle Scholar
• Rokach J, Kim S, Bellone S, et al. Total synthesis of isoprostanes: discovery and quantitation in biological systems. Chem Phys Lipids 2004; 128: 35–56
   PubMed Web of Science ®Google Scholar
• Ross BM. Phospholipid and eicosanoid signaling disturbances in schizophrenia. Prostaglandins Leukotr Essent Fatty Acids 2003; 69: 407–412
   PubMed Web of Science ®Google Scholar
• Rotrosen J, Wolkin A. Phospholipid and prostaglandin hypotheses of schizophrenia. Psychopharmacology. The third generation of progress, HY Meltzer. Raven Press, New York 1987; 759–764
   Google Scholar
• Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998; 71: 1002–1012
   PubMed Web of Science ®Google Scholar
• Souviget C, Cracowski JL, Stanke-Labesque F, Bessard G. Are isoprostanes a clinical marker for antioxidant drug investigation. Fundam Clin Pharmacol 2000; 14: 1–10
   PubMedGoogle Scholar
• Taber DF, Morrow JD, Roberts JL II. A nomenclature system for the isoprostanes. Prostaglandins 1997; 53: 63–67
   PubMed Web of Science ®Google Scholar
• Wachowicz B. Adenine nucleotides in thrombocytes of birds. Cell Biochem Funct 1984; 2: 167–170
   PubMed Web of Science ®Google Scholar
• van Kammen DP, Yao JK, Goetz K. Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann NY Acad Sci 1989; 559: 411–423
   PubMedGoogle Scholar
• Yao JK, van Yasaei P, Kammen DP. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 1992; 46: 39–46
   PubMedGoogle Scholar
• Yao JK, van Kammen DP, Gurkis WJ. Correlation of fatty acid abnormalities with clinical measures in schizophrenia. Schizophr Res 1994; 11: 124
   Google Scholar
• Yao JK, Reddy R, McElhinny LG, van Elhinny K. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998; 32: 1–8
   PubMed Web of Science ®Google Scholar
• Yao JK, Leonard S, Reddy R. Membrane phospholipids abnormalities in portmorten brains from schizophrenic patients. Schizophr Res 2000; 42: 7–17
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy RD, Kammen DP. Oxidative damage and schizophrenia. CNS Drugs 2001; 15: 287–310
   PubMed Web of Science ®Google Scholar